Absci

ABSI

Market cap $677M

Webinar on December 11 to feature leading KOLs in dermatology and hair loss alongside Absci leadership Phase 1/2a trial now expected to begin in December 2025, ahead of prior guidance VANCOUVER, Wash. and NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced the company will host a virtual seminar on December 11, 2025 at 10:00am ET focused on the company's ABS-201 (anti-PRLR) program for androgenetic alopecia.

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a promising trial or a drug that will make it to market—or crash and burn.

Absci Inc. ABSI on Thursday collaborated with Oracle Corporation's ORCL Oracle Cloud Infrastructure (OCI) and AMD Inc. AMD to accelerate generative AI-driven drug discovery.

Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costs Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costs

Absci Corporation (NASDAQ:ABSI ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 3:20 PM EDT Company Participants Sean McClain - Founder, CEO, President & Director Zachariah Jonasson - Chief Business Officer & CFO Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good afternoon, everyone, and welcome to Morgan Stanley's Global Healthcare Conference. I'm Sean Laaman, Head of U.S. MidCap biotech equity research.

World-renowned experts will guide the clinical development of ABS-201, a therapeutic antibody entering clinical trials for the treatment of androgenetic alopecia. World-renowned experts will guide the clinical development of ABS-201, a therapeutic antibody entering clinical trials for the treatment of androgenetic alopecia.

VANCOUVER, Wash. and NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the company will be participating in the following upcoming investor conferences:

Absci Corporation (NASDAQ:ABSI ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Alexander Khan - VP of Finance & Head of Investor Relations Christian Stegmann - Senior Vice President of Drug Creation Sean McClain - Founder, CEO, President & Director Zachariah Jonasson - Chief Business Officer & CFO Conference Call Participants Alexander Xenakis - Unidentified Company Truist Securities - Unidentified Company Arseniy Shabashvili - Guggenheim Securities, LLC, Research Division Brendan Mychal Smith - TD Cowen, Research Division Debanjana Chatterjee - JonesTrading Institutional Services, LLC, Research Division Gil Joseph Blum - Needham & Company, LLC, Research Division Morgan K. Gryga - Morgan Stanley, Research Division Steven Craig Dechert - KeyBanc Capital Markets Inc., Research Division Swayampakula Ramakanth - H.C.

Absci Corporation (ABSI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.22 per share a year ago.

Strengthened balance sheet raising approximately $64 million in gross proceeds in July 2025; cash, cash equivalents, and short-term investments now sufficient to fund operations into the first half of 2028